This gene lies adjacent to the tumor suppressor gene CDKN2A in a region that is frequently mutated, deleted, or disregulated in a wide variety of cancer. This gene encodes a cyclin-dependent kinase inhibitor, also known as p15Ink4b protein, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases by cyclin D, thus the encoded protein functions as a cell growth regulator that inhibits cell cycle G1 progression. The expression of this gene was found to be dramatically induced by TGF beta, which suggested its role in the TGF beta induced growth inhibition. Two alternatively spliced transcripts of this gene encode proteins that share the N-terminal sequence by but completely differ in the C-terminus.
^Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, et al. (October 2005). "Towards a proteome-scale map of the human protein-protein interaction network". Nature. 437 (7062): 1173–8. doi:10.1038/nature04209. PMID16189514. S2CID4427026.
Hall M, Bates S, Peters G (October 1995). "Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins". Oncogene. 11 (8): 1581–8. PMID7478582.
Stone S, Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright L, Kamb A (September 1995). "Genomic structure, expression and mutational analysis of the P15 (MTS2) gene". Oncogene. 11 (5): 987–91. PMID7675459.
Okamoto A, Hussain SP, Hagiwara K, Spillare EA, Rusin MR, Demetrick DJ, et al. (April 1995). "Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer". Cancer Research. 55 (7): 1448–51. PMID7882351.
Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, et al. (December 1994). "Deletion of p16 and p15 genes in brain tumors". Cancer Research. 54 (24): 6353–8. PMID7987828.
Iavarone A, Massagué J (May 1997). "Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15". Nature. 387 (6631): 417–22. doi:10.1038/387417a0. PMID9163429. S2CID1040022.
Tsubari M, Tiihonen E, Laiho M (July 1997). "Cloning and characterization of p10, an alternatively spliced form of p15 cyclin-dependent kinase inhibitor". Cancer Research. 57 (14): 2966–73. PMID9230210.
Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, et al. (April 2001). "Repression of p15INK4b expression by Myc through association with Miz-1". Nature Cell Biology. 3 (4): 392–9. doi:10.1038/35070076. PMID11283613. S2CID12696178.
Agiostratidou G, Derventzi A, Gonos ES (2002). "Over-expression of CDKIs p15INK4b, p16INK4a and p21CIP1/WAF1 genes mediate growth arrest in human osteosarcoma cell lines". In Vivo. 15 (5): 443–6. PMID11695244.
Simon M, Park TW, Köster G, Mahlberg R, Hackenbroch M, Boström J, et al. (December 2001). "Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression". Journal of Neuro-Oncology. 55 (3): 149–58. doi:10.1023/A:1013863630293. PMID11859969. S2CID19711721.
Scarisbrick JJ, Woolford AJ, Calonje E, Photiou A, Ferreira S, Orchard G, et al. (March 2002). "Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome". The Journal of Investigative Dermatology. 118 (3): 493–9. doi:10.1046/j.0022-202x.2001.01682.x. PMID11874489.